552 related articles for article (PubMed ID: 29417334)
21. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
[TBL] [Abstract][Full Text] [Related]
22. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
25. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
26. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
27. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
29. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
30. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Gerlach M; Desser H; Youdim MB; Riederer P
J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
[TBL] [Abstract][Full Text] [Related]
31. The pharmacology of selegiline.
Magyar K
Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
33. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Schapira AH
CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
[TBL] [Abstract][Full Text] [Related]
34. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
35. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
36. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
[TBL] [Abstract][Full Text] [Related]
37. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
38. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Finberg JP; Gillman K
Int Rev Neurobiol; 2011; 100():169-90. PubMed ID: 21971008
[TBL] [Abstract][Full Text] [Related]
40. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]